Seres Therapeutics, Inc. (MCRB) stock
MCRBNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.44+0.03 (+2.13%)
Close on Nov 18, 2026Market cap $14.32MP/E –Yield –
Seres Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Seres Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$84.03M. For fiscal 2025 it was -$93.97M. The highest annual figure on record is -$6.05M in fiscal 2013.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$93.97M | – |
| FY2024 | Dec 31, 2024 | -$121.32M | – |
| FY2023 | Dec 31, 2023 | -$195.10M | – |
| FY2022 | Dec 31, 2022 | -$179.91M | – |
| FY2021 | Dec 31, 2021 | -$64.49M | – |
| FY2020 | Dec 31, 2020 | -$88.13M | – |
| FY2019 | Dec 31, 2019 | -$71.88M | – |
| FY2018 | Dec 31, 2018 | -$100.28M | – |
| FY2017 | Dec 31, 2017 | -$91.40M | – |
| FY2016 | Dec 31, 2016 | -$92.84M | – |
| FY2015 | Dec 31, 2015 | -$54.86M | – |
| FY2014 | Dec 31, 2014 | -$15.08M | – |
| FY2013 | Dec 31, 2013 | -$6.05M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$21.27M | – |
| Q1 FY2026 | Mar 31, 2026 | -$20.91M | – |
| Q4 FY2025 | Dec 31, 2025 | -$19.38M | – |
| Q3 FY2025 | Sep 30, 2025 | -$22.48M | – |
| Q2 FY2025 | Jun 30, 2025 | -$24.88M | – |
| Q1 FY2025 | Mar 31, 2025 | -$27.24M | – |
| Q4 FY2024 | Dec 31, 2024 | -$28.84M | – |
| Q3 FY2024 | Sep 30, 2024 | -$29.17M | – |
| Q2 FY2024 | Jun 30, 2024 | -$28.87M | -158.3% |
| Q1 FY2024 | Mar 31, 2024 | -$34.44M | – |
| Q4 FY2023 | Dec 31, 2023 | -$37.02M | – |
| Q3 FY2023 | Sep 30, 2023 | -$44.59M | – |
| Q2 FY2023 | Jun 30, 2023 | $49.52M | – |
| Q1 FY2023 | Mar 31, 2023 | -$70.57M | – |
| Q4 FY2022 | Dec 31, 2022 | -$1.73M | – |
| Q3 FY2022 | Sep 30, 2022 | -$59.11M | -186.4% |
| Q2 FY2022 | Jun 30, 2022 | -$63.33M | – |
| Q1 FY2022 | Mar 31, 2022 | -$55.75M | – |
| Q4 FY2021 | Dec 31, 2021 | -$49.43M | – |
| Q3 FY2021 | Sep 30, 2021 | $68.41M | – |
| Q2 FY2021 | Jun 30, 2021 | -$48.14M | – |
| Q1 FY2021 | Mar 31, 2021 | -$35.33M | – |
| Q4 FY2020 | Dec 31, 2020 | -$17.90M | – |
| Q3 FY2020 | Sep 30, 2020 | -$30.00M | – |
| Q2 FY2020 | Jun 30, 2020 | -$20.55M | – |
| Q1 FY2020 | Mar 31, 2020 | -$19.69M | – |
| Q4 FY2019 | Dec 31, 2019 | -$19.19M | – |
| Q3 FY2019 | Sep 30, 2019 | -$17.18M | – |
| Q2 FY2019 | Jun 30, 2019 | -$10.95M | – |
| Q1 FY2019 | Mar 31, 2019 | -$24.55M | – |
| Q4 FY2018 | Dec 31, 2018 | -$21.67M | – |
| Q3 FY2018 | Sep 30, 2018 | -$22.21M | – |
| Q2 FY2018 | Jun 30, 2018 | -$28.14M | – |
| Q1 FY2018 | Mar 31, 2018 | -$28.27M | – |
| Q4 FY2017 | Dec 31, 2017 | -$29.78M | – |
| Q3 FY2017 | Sep 30, 2017 | -$7.31M | – |
| Q2 FY2017 | Jun 30, 2017 | -$28.42M | – |
| Q1 FY2017 | Mar 31, 2017 | -$25.89M | – |
| Q4 FY2016 | Dec 31, 2016 | -$25.69M | – |
| Q3 FY2016 | Sep 30, 2016 | -$19.10M | – |
See a number that looks wrong?